DR. RASHMI KUMARI

DR. BHAWESH SAHA

Abstract

Aim: The purpose of the study was to evaluate the IOP lowering effect and tolerability of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Material and Methods: This prospective, noncomparative, interventional case series study included 45 patients with POAG, poorly controlled with MMT. Ripasudil was instilled BD as adjunct to the ongoing glaucoma treatment. The primary end point was the degree of IOP reduction after 3 months of treatment, whereas the secondary end points were the percentage of patients reaching the predefined target IOP and adverse events. Results: . The IOP reduction was -2.9mm Hg after 3 months of treatment. . The adverse events were conjunctival hyperemia (all patients), allergic conjunctivitis (2 patients), and ophthalmalgia (1 patient). Conclusions: The addition of ripasudil was effective in lowering the IOP in patients with glaucoma poorly controlled with maximal medical therapy;